Negative Impact of Vapes on Public Health: WHO Calls for Urgent Action

Regulations by 2FIRSTS.ai
Dec.22.2023
Negative Impact of Vapes on Public Health: WHO Calls for Urgent Action
World Health Organization (WHO) states that there is no evidence that e-cigarettes effectively help smokers quit. Instead, evidence shows negative impacts on public health.

The World Health Organization (WHO) categorically states that there is no evidence to suggest that e-cigarettes can effectively assist community smokers in quitting smoking. On the contrary, there is existing evidence that indicates e-cigarettes have a negative impact on public health.

 

E-cigarettes have been widely available on the market and extensively promoted among young people. Currently, 34 countries have implemented bans on the sales of e-cigarettes, while 88 countries lack any minimum age restrictions for purchasing e-cigarettes. Additionally, 74 countries have no regulations in place regarding these harmful products.

 

World Health Organization Director-General Tedros Adhanom Ghebreyesus emphasized that "children are being lured into smoking and may become addicted to nicotine at a young age. I urge countries to implement strict measures to prevent the use of e-cigarettes in order to protect their citizens, especially children and adolescents.

 

E-cigarettes, which contain highly addictive nicotine, are harmful to health. While we have not yet fully understood their long-term effects on health, it has been established that they produce harmful substances, some of which are considered carcinogens, while others increase the risk of heart and lung diseases. The use of e-cigarettes may also affect brain development, leading to learning and cognitive impairments in young people. Pregnant women exposed to e-cigarettes may have adverse effects on the development of the fetus. The toxic gases in e-cigarettes also pose risks to those around the users.

 

The usage of e-cigarettes among children aged 13-15 is reported in all regions of the World Health Organization. In Canada, the prevalence of e-cigarette use among individuals aged 16-19 has doubled between 2017 and 2022. Similarly, in the UK, the number of teenagers using e-cigarettes has tripled in the past three years.

 

Research consistently indicates that even brief exposure to social media content about e-cigarettes can potentially increase both the willingness to use these products and the positive attitude towards e-cigarettes. Young people who use e-cigarettes are nearly three times more likely to use traditional cigarettes in the future.

 

The World Health Organization (WHO) has called on countries to take urgent measures to prevent the use of e-cigarettes and nicotine addiction, as well as to implement comprehensive tobacco control methods that align with each country's respective circumstances. In countries where the sale of e-cigarettes is prohibited, the WHO urges stronger enforcement of such bans and continuous monitoring to support public health interventions and ensure strict compliance. In countries where the sale of e-cigarettes as consumer products (including sales, imports, distribution, and production) is permitted, the WHO emphasizes the need for strict regulations to reduce their attractiveness and harm to the public. This includes the prohibition of all flavors, limitations on nicotine concentration and content, as well as taxation.

 

The strategy for smoking cessation should be based on the best available evidence and should be accompanied by other tobacco control measures, and it should be monitored and evaluated. According to the current evidence, the government should not allow the sales of e-cigarettes as consumer products in order to achieve the goal of smoking cessation.

 

Any government that adopts an e-cigarette smoking cessation strategy must regulate the conditions of product exposure to ensure proper clinical conditions and manage drug products (including requiring them to be distributed as pharmaceuticals). Even in such strict forms, the decision to pursue e-cigarettes as a means to achieve smoking cessation goals should only be made after reviewing domestic conditions, as well as examining smoking risks and proven cessation strategies.

 

Due to the growing prevalence of e-cigarette use, which has been found to have harmful effects on the health of children and adolescents, decisive action must be taken to prevent the use of e-cigarettes.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands Q3 Modern Oral Net Sales Rise 103% to $74.4 Million as Attributable Profit Falls 81%
Turning Point Brands (TPB) reported third-quarter 2026 Modern Oral net sales of $74.4 million on November 9, up 102.9% year over year and representing 49.2% of consolidated net sales. Total company net sales rose 27.0% to $151.1 million, while net income attributable to TPB declined 81.4% to $3.93 million. The company is expanding the US retail presence of its FRE and ALP nicotine pouch brands and expects its Modern Oral chain-store footprint to grow by more than 70% during 2026. Selling, general and administrative expenses increased 69.1% to $75.3 million, while PMTA-related expenses reached approximately $3.15 million and manufacturing start-up costs totaled about $593,000. ALP plans to open a branded pop-up in New York City's SoHo neighborhood on November 13, alongside a marketing campaign extending into January 2027. TPB owns 50% of ALP but consolidates the venture in its financial statements.
company
Nov.11
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
Product | KIWI Launches Spark 2 and Spark 2 Pro in Germany, Two Hardware Tiers Share Backward-Compatible 2ml Pods
KIWI has launched the Spark 2 and Spark 2 Pro refillable pod systems in Germany at official prices of €18 and €29, respectively. Spark 2 uses an 800mAh removable lithium-ion battery in a pen-style body, while Spark 2 Pro features a 1,400mAh removable battery, a box-shaped design and vibration feedback every 20 puffs. Both devices use the same 2ml Spark V2 pods in 0.8Ω and 1.2Ω versions, with AirSync airflow adjustment and a choice between Cotton Tips and conventional Drip Tips. The new pods also remain compatible with the original KIWI Spark.
News
Sep.29 by 2Firsts Perspectives
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
FDA Appoints Former Tobacco Enforcement Deputy Jessica Zeller as Director as Agency Weighs PMTA Framework Changes
The U.S. Food and Drug Administration (FDA) has named Jessica Zeller director of the Center for Tobacco Products' (CTP) Office of Compliance and Enforcement (OCE), effective November 1, 2026. Zeller, the office's inaugural deputy director, returns from medical device manufacturer Edwards Lifesciences with more than 20 years of regulatory and legal experience. The appointment follows CTP leadership changes and adjustments to tobacco regulation. Bret Koplow became permanent CTP director in September; the FDA revised enforcement priorities for unauthorized e-cigarettes and nicotine pouches in May and announced faster PMTA review procedures. On September 28, the agency said it would evaluate changes to the existing PMTA regulatory framework, including potential rulemaking to replace it.
FDA
Oct.20 by 2Firsts Perspectives
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
U.S. Health Groups Seek to Overturn FDA Enforcement Discretion for Pending PMTAs as Altria's Helix, NJOY and AVM Move to Intervene
American Vapor Manufacturers (AVM) and Altria subsidiaries Helix Innovations and NJOY filed separate motions on October 7, 2026, seeking to intervene on the FDA's side in a lawsuit challenging its enforcement guidance for certain e-cigarette and nicotine pouch products with pending premarket tobacco product applications (PMTAs). Seven public health and tobacco-control organizations, including the Campaign for Tobacco-Free Kids, sued the agency in July to overturn the policy. AVM argues that vacating the guidance could disrupt orders, inventory, retail distribution and investments in regulatory submissions.
Regulations
Oct.09
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's Vape Ban Decisions Reach 17 Regions With 39 More Considering Laws, Putting Over 3,000 St. Petersburg Retail Outlets in Focus
Russia's regional vape retail restrictions are expanding. State Duma Speaker Vyacheslav Volodin said on November 7 that 17 regions had adopted decisions to ban vape sales, while another 39 were preparing or considering similar legislation. On November 12, lawmakers in Leningrad Oblast and the Republic of Karelia adopted bans scheduled to begin on March 1, 2027. A day earlier, St. Petersburg unanimously approved a five-year ban proposal in its first reading. The city has 615 specialist vape shops and more than 2,400 other retail outlets selling vaping products alongside other goods. Under Federal Law No. 186-FZ, enacted in June 2026, Russian regions may prohibit retail sales of electronic nicotine delivery systems and related liquids between March 2027 and March 2032. The legislation also restricts licensed suppliers from delivering covered products to retail premises in regions where bans apply.
Regulations
Nov.13
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
FDA Revises Import Alert 98-07 Rules, Bringing May Enforcement Priorities Into Unauthorized ENDS Detentions
The U.S. Food and Drug Administration has revised the rules under Import Alert 98-07 to incorporate its May 2026 enforcement-priority policy for certain electronic nicotine delivery systems marketed without premarket authorization. The alert continues to allow detention without physical examination, or DWPE, for ENDS lacking required marketing authorization, while directing field divisions to apply the May risk-based framework. When necessary, detention or refusal decisions must also undergo review by the FDA's Center for Tobacco Products. Products including PACHA and Vuse Pro have already emerged as industry examples of the May policy, although enforcement discretion does not constitute FDA marketing authorization.
News
Sep.28 by 2Firsts Perspectives